-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Can Fite Biofarma, Lowers Price Target to $4

Benzinga·12/17/2025 12:42:05
語音播報
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and lowers the price target from $11 to $4.